Alzheimer's dementia statistics in women: why two-thirds of patients are female

She brought her mother to the appointment and sat very still while I asked about grocery lists and bill payments. Her mother answered every orientation question. Then she could not name the month. The daughter had been covering for months: managing medications, replaying conversations, turning down a promotion so someone would be home in the afternoons. "I thought it was just aging," she said. It was not. What I keep seeing is more women as patients and more women carrying the care around the disease at the same time.

Almost two-thirds of Americans living with Alzheimer's disease are women, according to the Alzheimer's Association. That figure shows up in press releases and policy briefs for a reason: it is stable and easy to quote. It is also incomplete without the numbers next to it. Lifetime risk, caregiving hours, diagnosis lag, and the dollar cost of a disease that stretches over years all belong in the same frame.

This article pulls those numbers from primary sources you can check: the Association's annual Facts and Figures reports, the Framingham Heart Study lifetime-risk analyses, peer-reviewed work on APOE ε4 and sex, and longitudinal data on how mild cognitive impairment progresses differently in women.

How common is Alzheimer's in women

Start with the prevalence figure reporters quote most often. Almost two-thirds of Americans with Alzheimer's are women. The 2025 Alzheimer's Disease Facts and Figures report, published in Alzheimer's & Dementia, estimates 7.2 million people age 65 and older with Alzheimer's dementia: about 4.4 million women and 2.8 million men, or roughly 12% of women and 10% of men age 65 and older. Association materials for the current cycle also state that about 1 in 9 people age 65 and older (11%) has Alzheimer's. Updated 2026 Association figures place the total near 7.4 million people 65 and older, including about 4.5 million women. The fraction (nearly two out of three) has held steady.

Alzheimer's accounts for an estimated 60% to 80% of dementia cases. Older Black Americans are about twice as likely as older White Americans to have Alzheimer's or other dementias, and older Hispanic Americans about one and one-half times as likely, per the same Association data. Sex and race compound; published counts that cut both ways remain thinner than they should be. Women in their 60s are more than twice as likely to develop Alzheimer's over the rest of their lives as they are to develop breast cancer, according to the Association's women-and-Alzheimer's briefing. That risk-perception gap still shows up in clinic every month.

Lifetime risk at 45 and 65

Prevalence counts who has the disease now. Lifetime risk asks a different question: if you reach a given age free of Alzheimer's, what is the chance you will develop it before you die?

Using Framingham Heart Study data through 2009, Chêne and colleagues estimated lifetime risk of Alzheimer's dementia at age 45 at approximately 1 in 5 (about 20%) for women and 1 in 10 (about 10%) for men. The Alzheimer's Association reproduces those estimates on its public facts page. Risks for both sexes are slightly higher from age 65. Framingham tables accounting for competing mortality put remaining lifetime Alzheimer's risk at age 65 near 21.1% for women and 11.6% for men; the Association summarizes a woman's risk at 65 as about 1 in 5. Those ratios are remaining-life probabilities in a carefully adjudicated U.S. cohort. They are not global rates and not one-year incidence. They remain the cleanest national-style figures a reporter can lift with the primary source named beside them.

Men have higher midlife cardiovascular mortality, so men who survive into the ages when Alzheimer's becomes common are, on average, a selected group. Framingham analyses found cumulative incidence looked more similar between sexes among people still alive and at risk, while lifetime risk still ran higher in women, especially after age 85. Selective survival of men with healthier cardiovascular profiles is one proposed mechanism. Part of the prevalence story is that more women live long enough for the disease to declare itself; part of the lifetime-risk gap reflects who dies of heart disease first. For that backdrop, see our coverage of heart disease statistics and risk factors in women.

Longevity is not the whole story

The honest answer is more careful than most headlines allow. Older age is the strongest risk factor for Alzheimer's, and women live longer than men on average. The Alzheimer's Association states that this survival difference contributes to higher prevalence in women. Most U.S. incidence studies (new cases among people of the same age) have not found a large, consistent female excess at every age. Some European studies report higher incidence among women at older ages; others do not. Region and survival differences muddy simple comparisons, as do birth cohort and education.

If a reporter asks whether it is "just longevity," the accurate reply is: longevity explains a large share of the higher prevalence, but it does not close the file. Lifetime risk remains roughly twice as high for women in Framingham-based estimates. Pathways into the disease may differ by sex even when age-specific incidence looks similar. Once mild cognitive impairment is present, progression is not sex-neutral.

Other candidates include hormonal factors tied to reproductive history, educational and occupational opportunity gaps in older cohorts, caregiving stress, and gene-by-sex interactions. Limited formal education is a dementia risk factor; historically lower attainment among women in earlier birth cohorts may still echo in today's counts, even as younger cohorts have closed that gap. The Association notes that educational gains for women over time appear linked to decreased dementia risk. Sleep disruption, midlife mood disorders, and the menopausal transition also sit in the conversation. None is a single cause. If you are already tracking midlife health, including cycle changes with our period calculator or reading about perimenopause symptoms, brain health belongs on the same checklist as bone and cardiovascular health.

APOE4, hormones, and biology

The best-characterized genetic risk factor for late-onset Alzheimer's is the ε4 allele of the apolipoprotein E gene (APOE). Everyone inherits one allele from each parent (ε2, ε3, or ε4). Roughly one in four people carries at least one ε4. Carrying ε4 raises risk relative to ε3; two copies raise it further. It is a risk gene, not destiny.

Sex modifies that risk most clearly in certain age windows. In a 2014 analysis of more than 8,000 people at Alzheimer's centers, Altmann and Greicius found that among initially cognitively normal older adults, a single ε4 copy conferred substantial risk of progressing to mild cognitive impairment or Alzheimer's in women, while the increase in men was only marginal. That was close to twice the likelihood of progressing for women carriers versus non-carriers.

A 2017 meta-analysis by Neu and colleagues in JAMA Neurology, pooling nearly 58,000 participants across 27 studies, nuanced the picture. Across ages 55-85 overall, men and women with ε3/ε4 had similar Alzheimer's odds (about 3.1 in men and 3.3 in women versus ε3/ε3). Between ages 65 and 75, women with ε3/ε4 had higher odds versus ε3/ε3 (OR 4.37) than men with ε3/ε4 did (OR 3.14). Elevated ε4-related MCI risk appeared earlier in women (ages 55-70). Two ε4 copies raised risk sharply in both sexes without a clear sex gap. The protective ε2 allele also appeared more protective in women.

Whether estrogen loss at menopause interacts with ε4 is still an open mechanistic question. The Alzheimer's Association notes it is unclear whether ε4's influence depends on estrogen, while funding programs such as the Women's Alzheimer's Research Initiative target sex biology and menopause. Earlier menopause has been linked to higher Alzheimer's-related risk in some cohorts, and midlife hormone therapy timing appears to matter. Midlife observational signals do not simply transfer to late-life initiation. That is a research frontier, not a prescription. Women considering therapy for menopausal symptoms should weigh the evidence in our menopause hormone therapy statistics piece with a clinician who knows their full risk profile. For women who already know they carry ε4, counseling should not treat their risk as identical to a male relative's with the same genotype.

Diagnosis delays in women

Diagnosis is where a statistical advantage becomes a clinical liability. Women, on average, outperform men on verbal memory tests, the same tests heavily used to detect amnestic mild cognitive impairment and early Alzheimer's. Sundermann and colleagues have shown that women with MCI can maintain better verbal memory scores than men despite similar hippocampal atrophy or hypometabolism. A woman may clear a standard cutoff while already carrying meaningful pathology, so MCI is labeled later, if at all.

Once impairment is recognized, the slope may be steeper. In Alzheimer's Disease Neuroimaging Initiative data, Lin and colleagues followed 398 people with MCI for up to eight years. After adjustment for baseline cognition, age, education, and APOE ε4, women worsened faster than men on ADAS-Cog and CDR sum-of-boxes. Annual ADAS-Cog change averaged about 2.7 points in women versus 1.5 in men, with a larger gender effect among ε4 carriers. Later recognition meeting a steeper slope is one reason women can appear to "crash" after a midstream diagnosis.

Sex-blind cutoffs on verbal tests are a blunt instrument. Researchers have proposed sex-adjusted norms; primary-care uptake is still uneven. Half of primary care physicians in Association workforce surveys say they do not feel adequately prepared to care for people with Alzheimer's, and 55% report too few dementia specialists in their communities. Families can shorten some lag by bringing a second historian, tracking missed bills and repeated questions in writing, and asking for cognitive screening. Midlife attention to sleep, blood pressure, and mood is not vanity. See our overview of sleep disorders and insomnia statistics in women.

The caregiving burden

Women are overrepresented on both sides of the exam table. According to the Alzheimer's Association, approximately two-thirds of unpaid caregivers for people with Alzheimer's or other dementias are women, and more than one-third of dementia caregivers are daughters. Women take on more caregiving tasks than male caregivers, often for people with greater cognitive, functional, or behavioral problems. There are 2.5 times more women than men who live full-time with the person who has dementia. Nearly 19% of women Alzheimer's caregivers report having quit work because of caregiving.

Scale that nationally. Association materials report nearly 13 million Americans providing unpaid care, with more than 19 billion hours in 2025 valued at more than $446 billion. The 2025 Facts and Figures journal report, using slightly earlier years, counted nearly 12 million caregivers providing 19.2 billion hours in 2024, valued at $413.5 billion. About 30% of caregivers are age 65 or older themselves; roughly one-quarter are "sandwich generation" caregivers. Fifty-nine percent report high to very high emotional stress. Of the total lifetime cost of caring for someone with dementia, about 70% is borne by families through unpaid care and out-of-pocket spending.

Caregiving is part of how Alzheimer's redistributes risk. The daughter who leaves the workforce loses income and retirement contributions, and often insurance quality. She may develop depression or anxiety that needs its own plan (see our women's mental health statistics on anxiety and depression). When policymakers talk about Alzheimer's costs, caregiver labor is most of the bill.

Cost of care

Dementia is one of the costliest conditions in U.S. health economics, and the invoice is split unevenly. The Alzheimer's Association projects health and long-term care costs for people living with Alzheimer's and other dementias at about $409 billion in 2026, not including unpaid caregiving. Medicare and Medicaid are expected to cover roughly $263 billion (about 64%), with out-of-pocket spending near $103 billion. Total payments are projected to approach $1 trillion by 2050. The 2025 journal report estimated about $384 billion for people age 65 and older with dementia in 2025. Same order of magnitude, different reference year.

Average Medicare payments for beneficiaries 65 and older with Alzheimer's or other dementias are almost three times as high as for those without these conditions; Medicaid payments are more than 22 times as high. People living with dementia have about twice as many hospital stays per year as other older adults. Lifetime cost of care for a person with dementia is estimated at about $405,262 in 2024 dollars, with roughly 70% falling on families. Public programs absorb much of the formal care. Families (disproportionately women) absorb most of the lifetime cost through labor and cash. Without major breakthroughs, the Association projects about 13.8 million Americans age 65 and older with Alzheimer's by 2060.

New anti-amyloid treatments and blood-based biomarkers may shift diagnosis earlier for some patients. They will not erase caregiving demand this decade. Between 2024 and 2034, nearly 800,000 additional direct care workers will be needed for people living with dementia. The Association describes that shortfall as the largest worker gap of any single U.S. occupation. Those shortages fall hardest on families who cannot buy their way out of them.

Frequently asked questions about Alzheimer's and dementia in women

What share of Alzheimer's patients are women?

Almost two-thirds of Americans living with Alzheimer's disease are women, according to the Alzheimer's Association. In the 2025 Facts and Figures report, that translated to about 4.4 million women and 2.8 million men among an estimated 7.2 million people age 65 and older with Alzheimer's dementia. Updated Association materials for 2026 cite roughly 7.4 million people 65 and older, including about 4.5 million women.

What is a woman's lifetime risk of Alzheimer's compared with a man's?

Framingham Heart Study data cited by the Alzheimer's Association estimate lifetime risk of Alzheimer's dementia at age 45 at about 1 in 5 for women and 1 in 10 for men. At age 65, a woman's estimated lifetime risk is still about 1 in 5 in Association summaries, with Framingham competing-risk estimates near 21% for women and 12% for men. These are remaining-life probabilities, not one-year incidence rates.

Does living longer fully explain higher Alzheimer's rates in women?

No. Longevity is the largest single reason more women than men are living with Alzheimer's at any moment, and the Alzheimer's Association says longer survival contributes to higher prevalence. Lifetime risk still runs roughly twice as high for women, and research on APOE ε4, menopause timing, verbal-memory test bias, and faster post-MCI decline points to additional sex-linked pathways. Age-specific incidence differences in U.S. studies are smaller and less consistent than the prevalence gap.

How does APOE4 risk differ for women?

Carrying one APOE ε4 allele raises late-onset Alzheimer's risk in both sexes, but several studies find a stronger or earlier effect in women. A 2017 JAMA Neurology meta-analysis found that between ages 65 and 75, women with ε3/ε4 had higher Alzheimer's odds versus ε3/ε3 (OR 4.37) than men with ε3/ε4 did (OR 3.14). A 2014 Annals of Neurology analysis found that among cognitively normal older adults, one ε4 copy substantially increased progression risk in women while the increase in men was only marginal. Two ε4 copies raise risk sharply in both sexes.

Why might Alzheimer's be diagnosed later in women?

Women often score higher on verbal memory tests used to detect mild cognitive impairment and early Alzheimer's, even when brain imaging shows atrophy or hypometabolism similar to men's. That advantage can mask early decline and delay an MCI label. Longitudinal ADNI data also show women with MCI declining faster than men on standard cognitive and functional scales, so later recognition can meet a steeper slope.

How much of the caregiving and cost burden falls on women?

About two-thirds of unpaid Alzheimer's and dementia caregivers are women, and more than one-third of dementia caregivers are daughters, per the Alzheimer's Association. Nearly 19% of women Alzheimer's caregivers report quitting work because of caregiving. Formal health and long-term care costs are projected near $409 billion in 2026, while unpaid care was valued above $400 billion in recent Association estimates, with about 70% of lifetime dementia care costs borne by families.